The $120 Billion Healthcare Opportunity Investors Can’t Ignore

5 min read

Welcome back to our latest edition of Market Insights with Sanjeev Kaushik.

Obesity has long been one of the world’s most stubborn and costly health crises. Traditional public health campaigns failed to curb its relentless rise — until now.

A new wave of powerful weight-loss drugs is transforming treatment outcomes and unlocking one of the fastest-growing investment opportunities in healthcare.

In this edition, we break down the winners and emerging players you need to watch out for. Let’s dive in.

1. The Obesity Market Revolution

What was once a small, niche pharmaceutical segment is now rapidly evolving into one of the biggest and most consequential markets in modern healthcare.

The obesity crisis, long regarded as an intractable public health issue, is being redefined by a new generation of anti-obesity medications.

Spearheaded by blockbuster drugs like Wegovy and Zepbound, these treatments are delivering life-changing results for patients — enabling weight loss of 15–20% and drastically reducing obesity-related health risks. Their commercial success has ignited a high-stakes race among pharmaceutical giants, biotech innovators, medtech companies, and digital health platforms to capture a share of what’s expected to be a $120 billion market by 2035.

1.1 From Crisis to Opportunity

According to the World Health Organization, global obesity rates have tripled since 1975. By 2023, over 1 billion adults worldwide were classified as overweight, with more than 650 million meeting clinical criteria for obesity. Left unchecked, the economic toll is staggering. Healthcare expenditures tied to obesity are forecast to surpass $4 trillion by 2035.

Historically, treatment options were limited to lifestyle modifications and, in severe cases, weight-loss surgery. Medications played a secondary role, often hampered by modest efficacy and significant side effects. That changed dramatically with the arrival of GLP-1 receptor agonists.

1.2 The Rise of GLP-1 Therapies

Originally developed for type 2 diabetes management, GLP-1 receptor agonists work by mimicking hormones that suppress appetite, slow digestion, and regulate blood sugar. Their application in weight management produced unprecedented outcomes in clinical trials.

The turning point came in 2021, when Novo Nordisk’s (NOVO-B) Wegovy received FDA approval, followed by Eli Lilly’s (LLY) Zepbound in 2023.

Patients on these therapies consistently achieved double-digit percentage weight loss — a feat unmatched by older medications.

Since then, the market has exploded:

• U.S. sales of GLP-1 obesity drugs grew from $1 billion in 2020 to an $18 billion annualized run rate by early 2025
• Global market forecasts project growth from $18 billion in 2024 to $120 billion by 2035

This positions obesity pharmacotherapy among the highest-growth categories in global healthcare, rivalling oncology and rare disease treatments in both scale and strategic importance.

1.3 Who’s Leading the Market

For now, the obesity drug market is essentially a two-horse race. Novo Nordisk and Eli Lilly dominate the space, commanding nearly 100% of branded GLP-1 sales for obesity treatment.

Novo Nordisk leads the pack, generating $8 billion from its obesity portfolio, which includes Wegovy, Ozempic, and Saxenda. Close behind, Eli Lilly has seen a powerful debut, with Zepbound and Mounjaro bringing in $4.9 billion in their first year alone.

But this duopoly faces mounting pressure. Global pharmaceutical majors, biotech startups, and generics players are all moving aggressively to claim their share of this rapidly expanding market — setting the stage for fierce competition and new market dynamics over the next few years.

1.4 The Next Generation of Obesity Treatments

The next disruption will come from oral GLP-1 therapies and multi-incretin agents (combining GLP-1, GIP, and glucagon activity). Pills promise greater convenience, reduced stigma, and broader adoption in primary care settings.

Eli Lilly’s orforglipron leads this category, with approval anticipated by 2026 and risk-adjusted sales projections exceeding $24 billion by 2035. Novo Nordisk’s oral semaglutide is close behind.

Meanwhile, biotech players like Viking Therapeutics (VKTX) and Amgen (AMGN) are trialing next-generation injectables with higher efficacy and monthly dosing schedules.

Notably, China, India, and South Korea are aggressively investing in GLP-1 development as patents expire in Western markets. Key entrants include:

• Livzon Pharma (1513.HK): Late-stage generic semaglutide
• Hansoh Pharma (3692.HK): Homegrown long-acting GLP-1
• AstraZeneca (AZN): GLP-1 oral pill candidate ECC5004

By 2030, branded drugmakers’ market share is expected to erode as these challengers scale production and secure local regulatory approvals.

1.5 A High Growth Investment Trend

Obesity therapeutics is now one of the highest-conviction themes in global healthcare.

Goldman Sachs estimates a compound annual growth rate (CAGR) of 27% through 2030, outpacing virtually every other major drug category.

Key reasons driving this growth include:

• A global rise in obesity prevalence
• Expanded insurance reimbursement in major markets
• High unmet medical need beyond the most severe obesity cases
• Rapid innovation in oral and multi-incretin therapies
• A growing addressable population of overweight individuals seeking preventive care

1.6 Risks Investors Should Monitor

Despite its momentum, the sector faces several notable risks:

• Supply bottlenecks: Both Eli Lilly and Novo Nordisk have struggled to meet surging demand
• Pricing and reimbursement pressures: With U.S. prices as high as $12,000–$15,000 per year, policy changes and price negotiations may squeeze margins
• New competitive entrants: China’s and India’s domestic drugmakers are aggressively developing biosimilars and generics
• Long-term adherence challenges: Approximately 30% of patients discontinue therapy within 18 months
• Regulatory scrutiny: Ongoing safety reviews around cardiovascular, thyroid, and gastrointestinal risks remain active concerns